These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

853 related articles for article (PubMed ID: 28934265)

  • 1. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
    PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
    Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
    J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
    Ludwig JM; Zhang D; Xing M; Kim HS
    Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Embolization alone is as effective as TACE for unresectable HCC: systematic review and meta-analysis of randomized controlled trails.
    Wang G; Zhang J; Liu H; Zheng Q; Sun P
    BMC Gastroenterol; 2024 Jun; 24(1):195. PubMed ID: 38849765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.
    Lobo L; Yakoub D; Picado O; Ripat C; Pendola F; Sharma R; ElTawil R; Kwon D; Venkat S; Portelance L; Yechieli R
    Cardiovasc Intervent Radiol; 2016 Nov; 39(11):1580-1588. PubMed ID: 27586657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
    Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Dhondt E; Lambert B; Hermie L; Huyck L; Vanlangenhove P; Geerts A; Verhelst X; Aerts M; Vanlander A; Berrevoet F; Troisi RI; Van Vlierberghe H; Defreyne L
    Radiology; 2022 Jun; 303(3):699-710. PubMed ID: 35258371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review.
    Yang B; Liang J; Qu Z; Yang F; Liao Z; Gou H
    PLoS One; 2020; 15(2):e0227475. PubMed ID: 32074102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.
    Oliveri RS; Wetterslev J; Gluud C
    Cochrane Database Syst Rev; 2011 Mar; (3):CD004787. PubMed ID: 21412886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; De Hertogh G; Deroose CM; Bonne L; Vandevaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2017 Dec; 40(12):1882-1890. PubMed ID: 28685382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.
    Wade R; South E; Anwer S; Sharif-Hurst S; Harden M; Fulbright H; Hodgson R; Dias S; Simmonds M; Rowe I; Thornton P; Eastwood A
    Health Technol Assess; 2023 Dec; 27(29):1-172. PubMed ID: 38149643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey.
    Akarca US; Akhan O; Bilgiç S; Bozkurt MF; Cantaşdemir M; Çermik TF; Çakaloğlu Y; Er Ö; Ilgıt E; Çapa Kaya G; Küçük NÖ; Numan F; Parıldar M; Türkmen C
    Diagn Interv Radiol; 2021 Nov; 27(6):732-739. PubMed ID: 34792027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard.
    Massarweh NN; Davila JA; El-Serag HB; Duan Z; Temple S; May S; Sada YH; Anaya DA
    J Surg Res; 2016 Feb; 200(2):552-9. PubMed ID: 26507276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Huo YR; Eslick GD
    JAMA Oncol; 2015 Sep; 1(6):756-65. PubMed ID: 26182200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Survival benefit with intraarterial techniques in hepatocellular carcinoma].
    Sangro B
    Gastroenterol Hepatol; 2014 Jul; 37 Suppl 2():95-101. PubMed ID: 25087719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of transarterial bland embolization and drug-eluting beads transarterial chemoembolization for very early and early hepatocellular carcinoma not amenable for surgery or ablation: a single center retrospective data analysis.
    Cathomas M; Mueller F; Mertineit N; Baumgartner I; Candinas D; Berzigotti A; Maurer MH; Lachenmayer A
    J Gastrointest Oncol; 2023 Oct; 14(5):2167-2177. PubMed ID: 37969817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review.
    Xie ZB; Ma L; Wang XB; Bai T; Ye JZ; Zhong JH; Li LQ
    Tumour Biol; 2014 Sep; 35(9):8451-9. PubMed ID: 25038916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.
    Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial Radioembolization versus Transarterial Chemoembolization Plus Percutaneous Ablation for Unresectable, Solitary Hepatocellular Carcinoma of ≥3 cm: A Propensity Score-Matched Study.
    Yu Q; Thapa N; Karani K; Navuluri R; Ahmed O; Van Ha T
    J Vasc Interv Radiol; 2022 Dec; 33(12):1570-1577.e1. PubMed ID: 36100064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.